cv
Merck diabetes drug gets CV trial boost
June 9, 2015Research and Development, Sales and Marketing Januvia, Merck, cv, diabetes, sitagliptin
Merck’s diabetes drug Januvia has been given a boost following worries over side effects for patients after a trial revealed …
Kowa launches new statin in the UK
August 20, 2010Sales and Marketing Kowa, Recordati, cv, statin
A new statin has been launched in the UK by Japanese pharma company Kowa.Livazo (pitavastatin) has been approved by the …
European approval for 3-in-1 version of Exforge
October 23, 2009Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension
European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …
New 2-in-1 Valturna outperforms Diovan
October 1, 2009Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension
Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …
Merck signs anticoagulant collaboration
July 17, 2009Research and Development, Sales and Marketing Merck, cv
Merck has continued the trend of big pharma companies signing on the dotted line with small biotech outfits in a …
Merck acquires rights to atrial fibrillation candidate
April 16, 2009Research and Development, Sales and Marketing Merck, cv
Merck has signed an agreement with Vancouver-based Cardiome Pharma to develop its new treatment for atrial fibrillation vernakalant.Merck will pay …
Bayer’s cardiovascular drug enters phase III
February 13, 2009Research and Development, Sales and Marketing Bayer, cv
Bayer Schering Pharma has begun phase III trials of riociguat for treatment of two life-threatening conditions. Two trials will investigate …
Crestor study has ‘profound implications’ for NICE guidance
November 14, 2008Sales and Marketing Crestor, cv, lipid
AstraZeneca's statin Crestor made national headlines this week when it was shown to dramatically reduce major cardiovascular events. New data …
Pradaxa approved by NICE
September 26, 2008Sales and Marketing NICE, Pradaxa, clot, cv
NICE has recommended Boehringer Ingelheim's novel anti-clotting pill Pradaxa, giving it a marketing edge over Bayer's rival treatment Xarelto. Pradaxa …
Experts play down Inergy cancer risk
September 5, 2008Sales and Marketing Merck, cv
Heart specialists have told patients to continue taking Schering-Plough and Merck's cholesterol-lowering drug Inergy, despite a study indicating that it …
Study confers protective benefits on Micardis
April 4, 2008Sales and Marketing cv
Boehringer Ingelheim's hypertension treatment Micardis has come out on top of Aventis's gold standard ACE inhibitor Tritace in a new …
Trial fails to enhance Inegy’s prospects
April 4, 2008Sales and Marketing cv
Schering-Plough and Merck's much-touted anti-cholesterol combination Inegy has suffered a setback following a poor showing in the ENHANCE trial. Inegy …
